Zobrazeno 1 - 10
of 13
pro vyhledávání: '"C Romero Delgado"'
Autor:
G Calzado Gómez, MA Navarro Davila, S Perez Reyes, C Romero Delgado, S Otazo Perez, Y Gonzalez Perez, M Bullejos Molina, GJ Nazco Casariego
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d535a54a0b6e88e8e9b099f9596cce8
https://doi.org/10.1136/ejhpharm-2023-eahp.455
https://doi.org/10.1136/ejhpharm-2023-eahp.455
Autor:
J Garcia Cairos, L Cantarelli, S García Gil, F Gutiérrez Nicolás, J Ramos Rodríguez, J González García, C Romero Delgado, G Calzado Gómez, GA González de la Fuente, B Del Rosario Garcia, GJ Nazco Casariego
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Therapeutic growth in the arsenal of drugs for the treatment of severe asthma (SA) with similar efficacy profiles, safety and mechanisms of action requires multidisciplinary treatment protocols to maintain the sustainability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9095ecdc9c4b906fd84393048fdc215b
https://doi.org/10.1136/ejhpharm-2020-eahpconf.31
https://doi.org/10.1136/ejhpharm-2020-eahpconf.31
Autor:
M. Pérez Campos, J Nazco Casariego, N Yurrebaso Eguior, M Bullejos Molina, S. González Ponsjoan, C Romero Delgado, G Calzado Gómez, T. Virgós Aller
Publikováno v:
Eur J Hosp Pharm
Background The commercialisation of fixed-dose combination meant an improvement in antiretroviral therapy (ART). With generics we have the opportunity to maintain the therapy at a lower cost, but we complicate the dosage regimen again. Purpose To ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab780a626c1b55531c3381281534838
https://europepmc.org/articles/PMC7535606/
https://europepmc.org/articles/PMC7535606/
Autor:
I Plasencia García, R Mesa Expósito, M Suarez Gonzalez, S Hernández Rojas, C Romero Delgado, J Merino Alonso
Publikováno v:
Pharmacokinetics and pharmacodynamics.
Background Administration of continuous infusion of vancomycin is an alternative to administration of this drug. Purpose To evaluate the clinical efficacy and incidence of adverse effects with a regimen of vancomycin as a continuous infusion. Materia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b876f1190657ab024fe2260012dab22c
https://doi.org/10.1136/ejhpharm-2017-000640.430
https://doi.org/10.1136/ejhpharm-2017-000640.430
Autor:
J Ramos Rodríguez, GA González de la Fuente, N Yurrebaso Eguilior, F Gutiérrez Nicolás, G Calzado Gómez, C Romero Delgado, GJ Nazco Casariego, M Bullejos Molina, S García Gil, MM Viña Romero
Publikováno v:
Clinical pharmacy.
Background Adalimumab is a subcutaneous anti-tumour necrosis factor antibody therapy used in the treatment of numerous pathologies related to rheumatology, dermatology and gastroenterology. This drug is on the top ranking of the annual hospital budge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a644fed1045ea053dbe9c304adf033
https://doi.org/10.1136/ejhpharm-2017-000640.180
https://doi.org/10.1136/ejhpharm-2017-000640.180
Autor:
G Calzado Gómez, C Romero Delgado, F Gutiérrez Nicolás, T. Virgós Aller, GJ Nazco Casariego, M Bullejos Molina, I González Perera
Publikováno v:
Clinical pharmacy.
Background Immunity to malaria is complex, due to the replicative cycle of the parasite through intracellular and extracellular phases. Cellular and humoral immunity are necessary to contain the infection; it is more complicated in patients who regul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fae5ca3c52276cc8163d03883151d02
https://doi.org/10.1136/ejhpharm-2017-000640.166
https://doi.org/10.1136/ejhpharm-2017-000640.166
Autor:
C Romero Delgado, JA de Leon Gil, M Suarez Gonzalez, G Calzado Gómez, J Merino Alonso, JA Martin Conde, M Kassih Ibrahim
Publikováno v:
Clinical pharmacy.
Background Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology. It is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma with forced expiratory volume in 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70839f4e039f792721d31923a90ea374
https://doi.org/10.1136/ejhpharm-2017-000640.17
https://doi.org/10.1136/ejhpharm-2017-000640.17
Autor:
J Nazco Casariego, G Calzado Gómez, M Suarez Gonzalez, M Bullejos Molina, N Roman Gonzalez, C Romero Delgado
Publikováno v:
Drug information and pharmacotherapy.
Background In recent years, new drugs have been approved for metastatic melanoma. The BRAF gene is the most common mutation in cutaneous melanomas and is present in 50% of melanomas. Vemurafenib and dabrafenib are used for the treatment of adult pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e48a4faadbe47e3cb805daf050b35d3
https://doi.org/10.1136/ejhpharm-2017-000640.277
https://doi.org/10.1136/ejhpharm-2017-000640.277
Autor:
C Fraile Clemente, E Gómez Melini, MA Navarro Dávila, M Suarez Gonzalez, JA Morales Barrios, C Romero Delgado, J Merino Alonso, E Ramos Santana, T Betancor García, A Montero Delgado
Publikováno v:
European Journal of Hospital Pharmacy. 23:A125.2-A126
Background Atypical haemolytic uraemic syndrome (aHUS) is a severe life threatening disease with progression to end stage renal disease. Eculizumab, a humanised anti-C5 monoclonal antibody targeting the activated complement pathway, has been introduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5830573b4ce2c839a95ca16217c9be0
https://doi.org/10.1136/ejhpharm-2016-000875.285
https://doi.org/10.1136/ejhpharm-2016-000875.285
Autor:
I González Perera, J Nazco Casariego, M Suarez Gonzalez, J González García, G Calzado Gómez, M Bullejos Molina, C Romero Delgado
Publikováno v:
European Journal of Hospital Pharmacy. 23:A147.2-A148
Background Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits the mitochondrial enzyme dehidroorotato-dehydrogenase (DHO-DH), which is required for the synthesis of pyrimidine, blocking the proliferation of act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::941650325abca3830cc00144ecf2233b
https://doi.org/10.1136/ejhpharm-2016-000875.333
https://doi.org/10.1136/ejhpharm-2016-000875.333